Thomas A. Macek

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

Richard S. Finkel, Claudia A. Chiriboga, Anne M. Connolly et al. · The Lancet Neurology · 2021 · 480 citations

Medicine, Genetics, Molecular Genetics +14

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni et al. · Nature Medicine · 2022 · 295 citations · Full text

Medicine, Genetics, Pediatrics +13

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni et al. · Nature Medicine · 2022 · 276 citations · Full text

Medicine, Genetics, Pediatrics +16

A 3‐week, randomized, placebo‐controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

Roger S. McIntyre, Miriam Cohen, Jun Zhao et al. · Bipolar Disorders · 2009 · 188 citations

Medicine, Pharmacology, Psychiatry +17

Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapses

Thomas A. Macek, Danny G. Winder, Robert W. Gereau et al. · Journal of Neurophysiology · 1996 · 182 citations

Life Sciences, Neurobiology, Neuroscience +17